Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 2

Tumour budding in preoperative biopsy specimens is a useful prognostic index for identifying high-risk patients in early-stage pN0 colon cancer

Pages
375–385
Publication Date
2020-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In univariate analysis, 5-year survival was poor in patients with high BD relaps-free survival [RFS]: 71 %, P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Tumour budding BD is considered a valuable prognostic factor in colon cancer CC , but its use in daily practice is uncertain.
📊
Key Findings & Data:Materials and methods: Eighty-two pN0 CC patients who underwent surgery after preoperative biopsy between 1997 and 2013 were included in the study.
💡
Conclusion & Impact:In univariate analysis, 5-year survival was poor in patients with high BD relaps-free survival [RFS]: 71 %, P
🔬Design:Modeling & Simulation
📍Scope:2013 Verileri
⚙️Variables:Tumour budding · colon cancer · preoperative biopsy

Abstract

Background/aim: Tumour budding BD is considered a valuable prognostic factor in colon cancer CC , but its use in daily practice is uncertain. We investigated the prognostic effect of BD using preoperative biopsy specimens in a fairly homogeneous population. Materials and methods: Eighty-two pN0 CC patients who underwent surgery after preoperative biopsy between 1997 and 2013 were included in the study. Model A using the `deeply invasive blocks & hot-spot area & invasive margin and method 1 using the `20× objective & immunohistochemistry staining & quantitive counting' were used as standard methods. Results: High BD was significantly associated with poor prognostic factors lymphatic invasion [P = 0.008], perineural invasion [P = 0.041], advanced pT [P = 0.015], invasive margin [P = 0.008], and margin involvement [P = 0.019] . Moreover, correlations between different BD estimates r = 0.613-0.696 , reproducibility of study Kappa = 0.68-0.73 , and usefulness of cut-off value area of under ROC = 0.746 [0.663-0.829] were well. In univariate analysis, 5-year survival was poor in patients with high BD relaps-free survival [RFS]: 71 %, P

🔖

Cite This Article

ZENGİN, M., ÇİFCİ, A. (2020). Tumour budding in preoperative biopsy specimens is a useful prognostic index for identifying high-risk patients in early-stage pN0 colon cancer. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 2, 375–385. https://ajindex.com/articles/113403

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76(2):182-188
  2. O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 2017; 18(7): 849-851
  3. Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(3): 370-398
  4. Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal Clinical Oncology 2018; 23: 1-34
  5. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. European Journal of Cancer 2018; 96: 54-63
  6. De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. British Journal of Cancer 2017; 116: 58-65
  7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-890
  8. Koelzer VH, Zlobec I, Lugli A. Tumour budding in colorectal cancer-ready for diagnostic practice? Human Pathology 2016; 47: 4-19
  9. De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Archiv 2016; 468: 397-408
  10. Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H et al. Prognostic value of Immunohistochemical analysis of tumour budding in colorectal carcinoma. Anticancer Research 2008; 28: 1831-1836
  11. Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. British Journal of Cancer 2016; 115: 831-840
  12. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G et al. Recommendations for reporting tumour budding in colorectal cancer based on the international tumour budding consensus conference (IBDCC) 2016. Modern Pathology 2017; 30: 1299- 1311 13. Gilardoni E, Bernasconi DP, Poli S, Garancini M, Luperto M et al. Surveillance for early stages of colon cancer: potentials for optimizing follow-up prot